Hosted on MSN

Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC

Sichan Kelun-Biotech Biopharmaceutical’s sac-TMT (sacituzumab tirumotecan) has posted positive results in a late-stage trial in non-small cell lung cancer (NSCLC). During the Phase III OptiTROP-Lung05 ...
Morningstar

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

INSIGHT-003 is evaluating eftilagimod alpha (efti) in combination with the anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) and doublet chemotherapy as first-line treatment for patients with advanced or ...
Cure Today

Perioperative Immunotherapy ‘Is The Revolution’ in NSCLC

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...
Precision Medicine Online

Merck to Test KRAS G12C Inhibitor With Keytruda in First-Line NSCLC

The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.
FiercePharma

Merck's partner Kelun touts phase 3 win for ADC-Keytruda combo in first-line lung cancer

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
Morningstar

Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint

CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded ...